Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They ...

Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor ...

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor ...

Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are ...

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor ...